Fifteen Years of Progress
Leveraging Resources FIFTEEN YEARS Accelerating Discovery OF PROGRESS Inspiring Hope 2007 Progress Report
pcf.org The Prostate Cancer Foundation (PCF) was founded in 1993 to find better treatments and a cure for recurrent prostate cancer. Through its unique model for soliciting and selecting promising research programs and rapid deployment of resources, the PCF has funded more than 1,500 programs at nearly 200 research centers in 20 countries around the world.
As the world’s leading philanthropic organization for funding prostate-cancer research, the PCF is now a foundation without borders. Its advocacy for increased government and private support of prostate cancer programs has helped build a global research enterprise of nearly $10 billion.
In 2007, 30 percent fewer men in the U.S. died from prostate cancer compared to what was once projected. The PCF is a force of HOPE for more than 16 million men and their families around the world who are currently facing the disease.
We have turned the corner. We will not give up. An end to death and suffering from prostate cancer is in sight.
Table of Contents Founder/CEO Letter 1 Research Highlights 3 Top Transformational 4 Discoveries New Strategies for 6 Accelerating Discovery Donors Roll 8 Cover Photos: The PhIP carcinogen molecule (yellow), damaging a DNA helix. Appeal for Support 14 PhIP, formed by charring meats at high temperatures, can insert itself into DNA, Donation Opportunities 15 causing errors in reading and replicating DNA. This can result in mutations that contribute to prostate cancer formation. Image from the diet and prostate-cancer Financial Statements 16 genetics research led by William G. Nelson, M.D., Ph.D., (pictured in the lower right) at the Johns Hopkins Medical Institutions. The discovery of PhIP as a major carcinogen Report of Independent 19 of prostate cancer – the potential equivalent of cigarette smoking in lung cancer – Auditors was made through PCF-supported research. Read about the scientific innovations of other PCF-funded researchers including Christopher Logothetis, M.D., University of Board of Directors 20 Texas M.D. Anderson Cancer Center (lower left), Robert Getzenberg, Ph.D., Johns and Leadership Team Hopkins (upper left), and Robert Langer, Sc.D., at MIT (upper right) in this report. Progress Report 15 Years of Turning the Progress for Prostate Corner: Cancer Research
Dear Friends, to $550 million from $27 million – a more than twenty-fold increase; the number of dedicated research labs has grown Fifteen years ago, the Prostate Cancer Foundation (PCF) from just three to more than 200; 18 nations now have was formed to discover better treatments and, ultimately, a prostate-cancer research centers, up from three; and once cure for prostate cancer. We believe attainment of this goal non-existent tissue banks now contain more than 20,000 is now within sight. samples for crucial scientific experiments. From the start, we understood that progress would not only 2. Scientific discovery is accelerating. require basic funding of prostate-cancer research, but a Back in 1993, there were no promising new drugs in comprehensive re-engineering of the processes that support the development pipeline. Today there are more than it. We developed an innovative model for rapid solicitation 20 new therapies in development and more than 60 new and review of research proposals, and accelerated deploy types of clinical trials each year. The number of ment of funding. Our grant recipients were required to share published research articles on prostate cancer published their data on a regular basis to stimulate scientific exchange last year reached 36,000 compared to 2,500 when the and speed discovery. We also committed to a strong PCF was founded. advocacy program for promoting government and private investment in prostate-cancer research and public awareness 3. Lifestyle changes capable of slowing disease of the disease. progression are emerging. PCF funding has stimulated some of the most rigorous nutrition and diet The foundation’s leadership has leveraged every dollar research of any cancer research funding agency during the many times over. Through the work of the PCF, and the past 15 years. From our inception, we have been interested efforts of its strategic partners around the world – medical in the link between lifestyle factors (diet and exercise) and institutions, government organizations, other foundations their effect on the occurrence and growth of prostate cancer. and private companies – prostate cancer has expanded from This area of investigation is one of our eight key areas of a neglected specialty to one of the most vibrant areas of funded research. More than 850 papers have now been biomedical research. Today’s global research enterprise for published on nutrition and prostate cancer, and $20 million prostate cancer represents nearly $10 billion in investments. is allocated annually by funding and research organizations During the past fifteen years, PCF-supported research has for cancer-related nutrition research. made a profound difference in the lives of prostate cancer 4. Most importantly, fewer men are dying. patients and medical professionals treating this disease. PCF-funded science, our advocacy for increased public Consider these accomplishments: funding, and heightened public awareness of prostate cancer 1. Prostate cancer has expanded from a neglected has resulted in fewer men dying from the disease. In 1995, specialty to one of the most significant areas of the American Cancer Society projected 40,000 deaths biomedical research. As a result of our advocacy, U.S. from prostate cancer in 2007. The reality was 28,000 – federal funding for prostate-cancer research has increased a reduction of 30 percent. We will continue this progress. 1 Progress Report
As we proceed, we will be able to build on our expanded adversely affect the return on our investments to date and base of prostate-cancer knowledge. PCF-funded researchers put scientific progress at risk. will gain a deeper understanding of the multiple molecular To realize our shared goal of eliminating prostate cancer, contributions to prostate cancer and develop more effective we need your ongoing commitment. Give us the tools – in and targeted drugs for every stage and type of the disease. the form of your continued financial support – and we will They will develop enhanced diagnostic and prognostic tools finish the job. that will better indicate which treatments are best suited to particular patients, and explore new, science-based Sincerely, preventive approaches.
The progress to date has been possible largely because of the foundation’s collaborative and multi-disciplinary model of science, our innovative reforms to traditional grant processes and funding strategies.
The PCF Inspires HOPE Our progress inspires hope for millions of prostate cancer patients and their families around the world. This hope is born of the commitment of the diverse PCF community: talented, innovative researchers; patients, survivors and their families; our corporate partners; and far-sighted venture philanthropists, who believe they will Mike Milken Jonathan Simons, MD achieve the best possible return on investment in prostate- Founder and Chairman President and Chief Executive Officer cancer research. David H. Koch Chair The following pages describe three major research projects we funded in 2007 and the top ten transformational discoveries in prostate cancer achieved through PCF funding. There is also a complete discussion of our new funding program.
Finally, in 2007, the PCF raised a record amount to fund crucial research programs that would not have been otherwise funded. While we’re determined to reach our goal and end the devastation caused by prostate cancer, U.S. federal funding for advanced cancer research, in real dollars, is declining for the first time in 15 years. Throttling back on the flow of research dollars now will
2 Progress Report research Highlights
In 2007, our fast-track approach to supporting scientific progress for prostate cancer continued. While committing funding for more than 86 research initiatives, we also conducted an extensive review of our Competitive Research Awards program. More than 40 prostate-cancer researchers participated in the ten-month review. As a result, we outlined a three-pronged research funding approach to advance the agenda of the PCF through 2012.
Advancing Research Models Logothetis, M.D., University of Texas M.D. The PCF Prostate Cancer Models Working Anderson Cancer Center; Kenneth Pienta, Group, comprising 13 former PCF competi- M.D., University of Michigan; and Robert tive-award recipients from 12 institutions, Vesella, Ph.D., University of Washington. met intensively at the PCF and published 3. Turning the Heat Up on State of the Science on Current Research Prostate Cancer Models in Prostate Cancer. This effort was During the past two decades, systematic conducted as a public service and provides a treatment with cytotoxic drugs or radiation comprehensive point of reference for testing therapy has cured some advanced, meta- new drugs. The report is a “state of the static cancers, such as testicular cancer. In science” of all prostate-cancer research mod- spite of these successes, no molecular targets els that was made available for university Acting like Trojan horses in the body, targeted nano have yet been identified to explain these particles show potential for delivering anti-cancer scientists and pharmaceutical and biotech- therapeutic successes. This PCF program nology investigators who want to enter the compounds directly into prostate cancer cells while avoiding healthy cells. will focus on learning about “what worked” field of prostate-cancer research. Underscor- in testicular cancer because – even with ing the PCF’s support of ahead-of-the-curve Subsequently, MIT team members received a extensive and advanced metastasis to the science, many of the new models forwarded special additional $650,000 Amplification brain and lungs – the vast majority of these by the team will be incorporated into drug Award from the PCF for the early completion patients are now successfully treated with and diagnostics development by the biotech- of milestones outlined as part of the Koch- systemic therapy and restored to long-term nology and pharmaceutical industries, as PCF Nanotherapeutics Challenge Award. normal health. Lance Armstrong, who went well as by the broader scientific community on to win the Tour de France seven times, is working on prostate cancer. Other team members are Philip Kantoff, one such patient. M.D., Dana-Farber Cancer Institute, and Most importantly, PCF-funded researchers Neil Bander, M.D., at Weill Medical An extensive analysis of scientific literature continued to make scientific breakthroughs College/Cornell University. indicates strong evidence that metatastic in the development of new prostate-cancer testicular tumor cells experience abnormal treatments. 2. Co-Targeted Drug Therapies: thermal (heat) stress when subjected to Three Novel Research Programs Hitting Two Achilles Heels at One Time normal body temperatures. The result is a Funded by the PCF Because few agents have been approved or heightened response to therapy by cytotoxic are currently in clinical trials for the preven- 1. Nanotechnology-based Solutions drugs, radiotherapy and immunotherapy. tion and treatment of bone metastases in Nanotechnology, involving materials smaller The team will explore the possibility of men with prostate cancer, there is a great than 100 nanometers (the size of atoms), directing heat only to cancer cells using need for better treatment strategies. One holds enormous promise for cancer research tumor-selected nanoparticles that can be approach is to combine drugs with different and patients. At this scale, materials exhibit heat-controlled by noninvasive external mechanisms of action. Sometimes it takes unique characteristics and properties, mak- energy sources such as magnetic fields. two or more drugs working together to kill a ing the use of nanoparticles a promising area prostate-cancer cell and innumerable drug This project is designed to be a highly for cancer detection, diagnosis and treat- combinations are possible. What’s needed is interactive program with expertise from ment. We are funding the world’s leading a way to prioritize possible drug combina- five institutions including MIT, Dana- team in nanoparticle delivery of prostate tions based on rigorous pre-clinical evalua- Farber Cancer Institute, the University of cancer medicines. The team is led by Robert tion. This two-year program will focus on Michigan, Johns Hopkins University and Langer, Sc.D., at MIT and Omid Farokzhad, evaluating combinations of drugs already The Prostate Cancer Center–Vancouver. M.D., at Brigham and Women’s Hospital. available for clinical trials in animal models. The Integrative Operational Coordinators This project is exploring if nanoscale par- are Robert H. Getzenberg, Ph.D., and ticles can act as Trojan horses in the body, The team of primary investigators for this Theodore L. DeWeese, M.D. of The Johns delivering medication directly to prostate- PCF-funded project includes: Theresa Guise, Hopkins University School of Medicine. cancer cells while bypassing healthy cells. M.D., University of Virginia; Christopher
3 Progress Report
Top Transformational Discoveries in Prostate-cancer research in 2007 The impact of scientific discoveries can be measured partly by the number of times a discovery is cited by other scientists who use the findings to push forward their own research. As a way of “keeping score,” the more a discovery is used by other cancer scientists, the more important it is. Cited by peers and selected for presentation of papers to annual American Association for Cancer Research meetings, the nine discoveries described below have transformed the field of prostate-cancer research in 2007. Each of these discoveries is a direct result of the PCF funding a high-impact/high-risk research idea through its Competitive Awards Program.
1. Genetics – William B. Isaacs, Ph.D., at Johns Hopkins and Xiangfeng Xu, Ph.D., of Wake Forrest University discovered regions of DNA in the human genome that can predict a ten-times higher lifetime risk for prostate cancer. Once this is confirmed in broader populations, a simple saliva test or blood test could provide a useful predictive test for men with a family history of prostate cancer. For sons and grandsons of fathers who carry genes for prostate cancer, this could become a lifesaving test. Dr. Isaacs has been a recipient of PCF Competitive Research Awards since 1995.
2. Activating the Immune System Against Prostate Cancer – Eugene Kwon, M.D., at the Mayo Clinic, identified three new “brakes” in the male immune system that prevent a patient’s immune system from seeing and attacking prostate cancer. These brakes must be lifted for the patient’s immune system cells to “see” the prostate cancer as a foreign invader and eradicate it. The “brake” (B7H3) may be released using new therapeutic agents that could block the function of B7H3. This discovery opens the door for developing new drugs to awaken proper immune responses.
3. A Better “Detector Test” for Prostate Cancer – Robert Getzenberg, Ph.D., at Johns Hopkins University, has discovered that a protein called EPCA-2 is a novel biomarker associated with prostate cancer and that it is detectable in the blood. The PSA test detects prostate diseases including prostate cancer but is not specific to prostate cancer. Many patients undergo biopsies with an elevated PSA blood test that do not have prostate cancer. In contrast, EPCA-2 is produced only by prostate cancer cells. If it is found in the blood it means cancer is present. EPCA-2 also has sensitivity and specificity, enabling it to differentiate between men with organ-confined and non-organ-confined disease. Dr. Getzenberg has been a recipient of PCF Competitive Research Awards since 2005. As a result of this proteomics discovery in prostate cancer, patients and doctors may soon have an effective new blood test for initial detection and subsequent monitoring of EPCA-2 to follow remissions after treatment.
4. Targeted Therapies – Arul Chinnaiyan, M.D., Ph.D., and his colleagues at the University of Michigan, discovered an “on-switch” – a case of a chromosomal translocation and fusion of two unrelated genes (TMPRSS2 and ERG) that is unique to prostate cancer. The finding has garnered multiple research prizes and unearthed an entire new way of understanding how prostate cancer is “turned on” in normal cells. The ERG gene itself is now indicated as a key gene to block with targeted medicines. The team is now developing a system to screen hundreds of molecules that might inhibit activity of ERG. Further, because the fusion of these genes is detected easily and unique to prostate cancer, they are good targets for cancer-killing therapies that could destroy prostate cancer cells without damaging healthy cells. Research is also underway to develop a simple urine test to detect prostate cancer earlier than PSA does by detecting the chromosomal fusions. For patients, this is a landmark molecular finding that can guide precisely which treatments are best matched for them. Dr. Chinnaiyan has been a recipient of PCF Competitive Research Awards since 2001.
4 Progress Report
5. STAT5 A New Target for Drug Therapy – Edward Gellmann, M.D., at the Columbia University Medical Center identified a new path linking the STAT5 “inflammatory pathway” gene to the action of androgen receptors in hormone-resistant prostate cancer. STAT5 is a key molecule involved in normal inflammation and tissue-wound repair. In hormone-resistant prostate cancers it is “hijacked” and can replace or boost testosterone action on androgen receptors. This enables hormone-resistant cancer cell clones to survive and grow. New drugs targeting STAT5 are now a compelling research area for co-targeting research. Dr. Gellman has received PCF Competitive Research Awards since 1994.
6. Biomarkers of Metastatic Disease – A key genetic change in prostate cancer is the loss of the PTEN gene that may be involved with metastasis. PTEN-mutated prostate cancers are responsible for many deaths from prostate cancer each year. Charles Sawyers, M.D., at Memorial Sloan-Kettering Cancer Center, discovered a marker in the blood known as Insulin Growth Factor Binding Protein 2 that is associated with PTEN-mutated tumors. For patients, this could mean earlier diagnosis of metastatic disease activity in the bone. Starting treatment earlier (compared to bone scans) could be a large therapeutic advance in some patients. An analytic blood test that employs a proteomics-based technology to detect microscopic cancer growth is possible given this finding. Dr. Sawyers has received PCF Competitive Research Awards since 1996.
7. Nutritional Sciences – William Nelson, M.D., Ph.D., at Johns Hopkins, discovered that a major carcinogen (PhIP) found in charred, grilled meats appears to accumulate in the area of the prostate that later develops prostate cancer. PhIP has the same DNA mutational capacity as cigarette smoke but the carcinogen accumulates only in the prostate. This finding has triggered major new studies on the healthiest way to cook meats in order to protect the prostate from accumulating carcinogens over a lifetime. Ultimately, further research into why PhIPs accumulate in the prostate may change dietary recommendations, help reduce the incidence of prostate cancer and protect men from prostate cancer starting at an early age. Dr. Nelson has been a PCF Competitive Research Award Recipient since 1993.
8. Intracrine Androgens – Peter Nelson, M.D., and Elahe Mostagel, M.D., Ph.D., at the Fred Hutchinson Cancer Research Center and the University of Washington, determined that not all patients undergoing hormone therapy may achieve full suppression of androgens. Some tumor microenvironments may create survival testosterone chemically from normal cholesterol. In 50 years of research on testosterone in prostate cancer biology, this possibility was not scientifically tested until Dr. Nelson and his colleagues conducted these studies. The development of new therapeutic agents to block this “intracrine androgen” could benefit more than 50,000 U.S. men annually whose tumors are resistant to current hormonal therapies. Dr. Nelson has been funded by PCF Competitive Research Awards since 1999.
9. Antioxidants and Prostate Health – Oxidation damages biological molecules and causes prostate cancers. Consumption of foods rich in antioxidants, if those antioxidants can leave the stomach, enter the bloodstream and penetrate the prostate, may counteract oxidative stress and provide beneficial effects against cancer. David Heber, M.D., Ph.D., at UCLA, demonstrated that several large antioxidant molecules called polyphenols exist in strawberries. Whole strawberry extract and the individual polyphenols isolated from strawberry extracts slowed proliferation of prostate, oral and colon cancer cell cultures. Response to purified polyphenols is dose-dependent and related to the antioxidant activity of each compound. A new science is emerging for prostate cancer prevention that views components of foods scientifically and as agents that may reduce the incidence of prostate cancer. Dietary recommendations and rigorous studies of which compounds and supplements should be incorporated into the diet is emerging. These dietary recommendations may be particularly important to the men carrying genes for prostate cancer. Dr. Heber has been a recipient of PCF Competitive Research Awards since 1994.
5 Progress Report New Strategies for Accelerating Discovery
PCF Competitive Awards, introduced in 1993, revolutionized the and fulfilled our initially-stated 1993 goals, we decided to develop way research is evaluated and funded, empowering many young a new strategy to build upon the initial success. More than 40 scientists to fill the pipeline of innovation with new diagnostic and prostate-cancer research experts and experts in biotechnology therapeutic tools. This model has proven enormously successful: were involved in developing the new strategy. By the end of 2007, There is virtually no new scientific idea or product in development we introduced a strategy designed to focus on specific assets in the or on the market for prostate cancer that has not been supported at field of prostate-cancer research. It will build a sustainable and least in part by PCF funding. As a direct result of our support and dynamic research enterprise comprising cross-disciplinary teams advocacy, the scientific and medical community has turned the working on multi-year programs and drive our efforts to develop corner on prostate cancer. We believe an end to death and suffering new, effective therapies for eradicating this disease. from this disease is in sight. The resulting funding programs are designed to replace our To ensure that we ultimately attain our goal of eliminating death former Competitive Research Awards Program. Each of the from prostate cancer, we conducted a comprehensive review of our programs is unique with individual goals and objectives designed competitive awards programs from 1993 to 2006. While the review to integrate with each other and, most importantly, to be scalable concluded that the awards program performed exceedingly well and self-perpetuating.
PCF Research Enterprise 2007/2008
Human Creativity Challenge Awards “First-in-Man” Capital Awards Therapeutic Initiatives Clinical Investigation
Prodigy Awards (3) Individual 2008 Challenge Awards 8 centers 3-year $450,000 Investigators (25) 3-year $20,100,000 investment $3,200,000 annual investment $2,500,000 annual Progression Biomarkers Discovery and Validation investment investment Recognition Intracrine Androgens and Androgen Receptor Awards (4) Signaling (Scientific meetings) Nutrition, Metabolism and Patient Quality of Life $40,000 annual ETS Gene Fusions investment Prostate Cancer Stem Cells 2008 PCF Young Epigenetics Investigator Immunotherapy Awards Predictive Preclinical Models 3-year $4,700,000 investment 2007 Special Challenge Programs 5-year $12,100,000 investment* EPCA-2 Biomarkers Research & Development *OHNS (OPKINS 5NIVERSITY Koch PCF Nanotherapeutics -)4(ARVARD#ORNELL PCF Safeway S.T.A.R. Program: Thermal Enhanced Metastatic Therapy *OHNS (OPKINS 5NIVERSITY Prostate Cancer Genomics 4RANSLATIONAL 'ENOMICS 2ESEARCH )NSTITUTE Proteomics Technology Development 3PIELBERG &AMILY #ENTER FOR !PPLIED 0ROTEOMICS n #EDARS 3INAI *Some award recognition will occur in future years.
6 Progress Report
1. The Prostate Cancer Foundation Human potential but currently without funding. These are meant to provide Capital Initiative short-term, high-risk/high-reward support, generally going to Our most valuable asset has always been and will continue to be individual investigators. They are complementary and integrated human capital. We have been successful in identifying promising with other PCF award programs. In the past, more than 70 percent of young investigators who are now mid-career leaders in the field of these one-year awards converted into stand-alone research programs. prostate cancer. To get us to our goal requires identifying and devel- 3. PCF Challenge Awards oping the next group of visionary research leaders – a task made The explosion of biological data over the past few years holds great even more crucial with the current reductions in government fund- promise, but no single individual, laboratory, or even institution can ing. To that end, we are launching a series of awards aimed at build- bring the resources needed to turn the data into useful knowledge for ing the next generation of prostate cancer scientific leaders. understanding, preventing, or treating prostate cancer effectively. Key Principles Behind the Human Capital Initiative A new model of science, similar to the one that produced the Human n Human capital is our most valuable asset. Genome Project, is needed: teams of talent with multidisciplinary researchers who can take new discoveries from the bench into the n Most important discoveries come from scientific investigators younger than 35 years old. clinic, or can develop the crucial tools for the entire research com- munity that empower individual researchers to take on the questions n perpetuating promising careers has become difficult in the current that still need to be answered. funding environment. The PCF Challenge Awards are designed to increase the impact of n The PCF has had success in identifying the current leaders who PCF funding by making larger investments in multi-year projects are now in mid-career. with high transformative potential for areas of unmet needs in pros- n We need to identify the next group of research leaders, especially tate-cancer research. These awards, chosen through expedited peer M.D., Ph.D. translational scientists. review by relevant experts, outline prescribed milestones and require n support of young investigators is an attractive opportunity for yearly results presentations. donors. PCF Prodigy Awards 2008 Spending Allocations Patterned after the MacArthur Foundation’s Fellows awards, PCF Since our founding, we at the PCF have always believed in the rapid Prodigy Awards will go to emerging prostate-cancer research deployment of maximum funding to support scientific research in “superstars” in their thirties who have demonstrated extraordinary the fight against prostate cancer. In 2008, every dollar donated to the originality and dedication to their field. They will provide additional foundation will be invested as follows: support to develop recipients’ careers. Recipients will have just completed their medical research training and will have demonstrat- $0.79 ed talent, drive and potential for greatness at an early age. Prostate Cancer Research Mission PCF Recognition Awards $0.73 $0.06 The Recognition Awards will be given to investigators, not currently Research Grants & Public Education Programs Support & Advocacy funded by the PCF, for outstanding accomplishments in prostate cancer research presented at major medical meetings. These awards are intended to help integrate recipients with PCF researchers and to help drive their findings into clinical practice.
PCF Young Investigator Awards $0.13 Fundraising Inspired by Donald S. Coffey, Ph.D., who has trained more than 30 of today’s leading prostate-cancer researchers, these awards will offer career support for young, proven investigators who have already achieved faculty positions and are committed to the field of prostate cancer. $0.08 Administration 2. PCF Creativity Awards Similar in spirit to our former one-year Competitive Research Awards, the PCF Creativity Awards allow the development of creative prostate-cancer science, i.e., scientific ideas with high
7 Progress Report
A Special Thank you The Prostate Cancer Foundation would like to thank everyone who has supported us over the last fifteen years. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 since our inception.
Founders Kern Family Fund Dennis and Phyllis Washington Solomon Kerzner ($50,000,000+) David E. and Beth Kobliner Shaw Foundation Michael and Jena King Milken Family Foundation C. Michael and Elizabeth Kojaian Gary and Karen Winnick W. C. Klintworth Richard N. Merkin, M.D. Knowledge Universe Founder’s Circle Gordon E. Moore Partners Richard S. and Karen LeFrak ($2,000,000 - $49,999,999) Movember, Inc. ($100,000 - $249,999) Charitable Foundation W. Howard and Mary Lester Anonymous (2) Bruce and Jeannie Nordstrom Anonymous (1) Solomon and Rosie Lew Leon and Debra Black Novartis Pharmaceuticals Corporation William and Donna Acquavella Peter B. Lewis Jamie B. Coulter Lewis and Peg Ranieri The G. Chris Andersen Family Foundation William and Phyllis Mack David and Julia Koch Ellen and Richard V. Sandler, Esq. Phillip and Nancy Anschutz Major League Baseball Charity, Inc. Thomas H. Lee and Ann Tenenbaum Sanofi-Aventis Ambassador George L. Argyros, Sr. Marin Community Foundation Carl Lindner Mickey and Karen Shapiro Arnie’s Army Battles Prostate Cancer Leni and Peter May Lowell Milken Lester and Sue Smith Foundation Atlanta Hawks Bruce R. and Jolene M. McCaw Fund Michael and Lori Milken Edward M. Snider The Lynn Aymar Family Foundation George A. Mealey The News Corporation Foundation Stuart Subotnick Chris and Tory Bagdasarian Robert A. Meister Stewart and Lynda Resnick Tarnopol Family Foundation, Inc. Charles F. Baird, Jr. Lowell Milken Safeway, Inc. Yahoo! Robert and Donna Baldwin Avram Miller Stephen and Elaine Wynn Stanley and Barbara Zax The Cecile and Fred Bartman Foundation Ron and Judy Baron S. Leslie and Barbara Misrock Leadership Circle Patrons Charles and Michelle Becker Kenneth and Julie Moelis ($1,000,000 - $1,999,999) ($250,000 - $499,999) Marc R. Benioff Jay and Elaine Moorin, Alain and Iris Braman Family Foundation Schreiber, and ProQuest Investments Anonymous (5) Joseph and Annette Allen Gary S. Broad John and Rebecca Moores Abbott Laboratories Brian and Kathleen Bean The Brookdale Foundation Moore Family Foundation Aventis Pharmaceuticals, Inc. Bloomberg L.P. John and Barbara Burns Marc and Jane Nathanson Bristol-Myers Squibb Company The Eli and Edythe Broad Foundation August A. Busch IV Nativity Jesuit Middle School Charles F. Dolan James and Patricia Cayne Callaway Golf Sales Company Linden Nelson William L. Edwards Stephen and Chantal Cloobeck California State Council of Laborers James Newman Edward P. Evans Foundation L. John Doerr CAO International, Inc. John and Sally Nordstrom Andrew S. Grove David and Marsha Ederer Cendant Corporation George and Sandra Norcross Sidney Kimmel The Gillette Company Max C. Chapman, Jr. OSI Pharmaceuticals Rush Limbaugh Harkins Charitable Gift Fund John and Jennifer Chalsty Joel M. Pashcow The Lincy Foundation Heinz North America Robert D. Collins Fund Rick Pitino Carol and Earle I. Mack Steven and Tomisue Hilbert Concern Foundation Bruce I. Raben Charles N. Mathewson Foundation The R.D. and Joan Dale Hubbard Foundation The Carole & Robert Daly Charitable Sumner and Paula Redstone The Craig and Susan McCaw Foundation Ray and Ghada Irani Foundation William A. Richardson Nelson and Claudia Peltz Peter W. Janssen Thomas and Gun Denhart Lew Rothman Ronald O. Perelman Michael Jordan James and Kristin Dolan Marc J. and Carolyn Rowan PGA Tour Charities, Inc Kissick Family Foundation Dunwoody Senior Men’s Golf Association The Rachel and Lewis Rudin Family Cliff and Debbie Robbins Charles G. Koch Durden Foundation Foundation, Inc. Julian H. Robertson, Jr. Herb and Natalie Kohler Jeremy D. Eden Larry W. Ruvo William A. Schwartz Robert A. Kotick Lee and Daniele Einsidler Haim and Cheryl Saban Jane and Terry Semel Kovler Family Foundation Don Engel The San Francisco Foundation M. Shanken, Chairman / Ernst & Young LLP San Francisco Giants M. Shanken Communications, Inc. Lamkin Corporation Robert S. Evans J. Gary and O.J. Shansby Foundation Thomas Spiegel Gary and Tina Lowenthal Jeffrey A. Marcus William F. Farley David and Janelle Shaffer Wade F.B. Thompson Charitable Shoes for Crews, LLC Foundation F W McCarthy Foundation Ralph and Cynthia Finerman Medical Research Agencies of America Friendship Foundation, Inc. Silent Partners Inc. Ted and Dani Virtue Skull Creek Development Martin and Pamela Wygod Richard Mejasich Richard S. Fuld, Jr. MidOcean Partners The David Geffen Foundation Eric and Susan Smidt David M. Solomon Benefactors Joy and Jerry Monkarsh Family Gen-Probe Incorporated Martin & Toni Sosnoff Foundation ($500,000 - $999,999) Foundation Genentech Foundation Sandra and Lawrence Post Family Eric and Anne Gleacher Alex G. Spanos Anonymous (3) Foundation Thomas and Holly Gores The John R. & Inge P. Stafford Foundation Advance Magazine Group Brian and Patricia Reynolds Orland S. Greene Joe Fred Starr Robert K. Barth Leonard and Louise Riggio Wayne and Janet Gretzky Joseph and Diane Steinberg Baume & Mercier Co. Gene and Marianne Salmon Greenbriar Golf Association 1992 Charitable Trust The Bunker Foundation Sanofi-Synthelabo Martin and Audrey Gruss Ernest E. Stempel Ronald W. Burkle The John F. Scarpa Foundation Richard B. Handler Avy and Marcie Stein Winston H. Chen, Ph.D. Melvin and Bren Simon Charitable Joseph W. Harch The Stern Family Foundation Conde Nast Publications, Inc. Foundation No.1 Thomas O. Hicks Roger and Susan Stone Lawrence J. Ellison Paul and Elle Stephens Hilton Hotels Corporation Swing for the Cure Christian B. Evensen Sterling Equities Leo Hindery, Jr. Marty Tenenbaum Sue Gin Robert & Jane Toll Foundation Hugo Boss Fashions, Inc. Laurence and Billie Tisch D. Wayne and Anne Gittinger Warren and Jale Trepp Jon and Karen Huntsman Tom and Diane Tuft Golfers Against Cancer Clyde T. Turner Carl and Gail Icahn Barbara Tyson The Greenspun Family Foundation Leslie L. Vadasz Richard and Deborah Justice Van Van Auken Guggenheim Investment Varian Medical Systems, Inc. David Karpol The Wagner Family Foundation Management, LLC Robert and Angela Voss Mel and Terry Karmazin Raul and Vicki Walters Peter Karmanos, Jr.
8 Progress Report
Wasserman, Comden, Casselman & John and Kathleen Gorman Stephen A. Schwarzman Michael Dougherty Pearson, LLP GPC Biotech Thomas J. Shannon, Jr. Efficiency Enterprises Thomas and Emily Weisel The Sam and Sarah Grossinger Jeffrey and Helaine Silverstein Harvey P. Eisen Will Weinstein Foundation Herb Simon Lewis M. Eisenberg John F. Welch, Jr. Allen Grubman Paul and Celia Sirotkin Lawrence R. Elins Jim and Kim Williams Norb Guziewicz Stuart M. Sloan The Entertainment Industry Foundation Sam Zell J. Ira and Nicki Harris Jeff P. Smith Thomas J. Fazio Selig Zises Alan and Vivien Hassenfeld The Snider Foundation Ferolito, Vultaggio & Sons Houston Golf Association Don Soffer Cary Fields Associates Roy W. Howard Southern California District Council Steve Fink ($50,000 - $99,999) James Hudson of Laborers Alex Fisher Anonymous (5) Jim Beam Brands Co. James Stern Peter E. Fleming, Jr. Robert W. Adler Joseph H. Kanter Foundation Saul P. Steinberg Todd Follmer AJA Charitable Fund Matthew Kaplan Sternlicht Family Foundation Theo and Constance Folz Edward C. Allred Bruce E. Karatz Louis B. Susman John R. Frank Robert and Jodi Allardice John Kelley Allan Tessler Keith Frankel Altadis USA, Inc. Melvyn N. Klein William H. Tilley Robert Fremont Anaheim Angels David and Janet Kline Fund Time Inc. Jim Freer Eric J. Aronson The Kobrand Foundation Joe and Alice Torre Jerry Friedman Michael and Marlene Aufrecht Fred Kolber Jeanette Trepp Steven Friedman Facundo L. Bacardi Timothy Koogle Trimaran Capital Partners Carlos Fuente, Jr. Mr. and Mrs. Robert Baker Family Dewanto Kurniawan Vadasz Family Foundation Paul R. Garcia Foundation Laborers’ International Union of Clark Van Nostrand Philip H. Geier, Jr. Roger Barnett North America Alice Walton Davidoff of Geneva Kathy and Frank Baxter Emeril Lagasse Mr. and Mrs. Jay L. Wallberg Stephen and Mindy Geppi Erin and Douglas Becker Kenneth and Linda Lay Cheng Ching Wang Charles and Vivian Gillespie Samuel Belzberg The Leeds Family Foundation Casey and Laura Wasserman Givingcapital LLC Marshall Bennett Lehman Brothers, Inc. Jerry and Jane Weintraub Goldentree Asset Management Ken Berg Robert Levin Gary and Nina Wexler Bruce Goldstein Phyllis and Martin Berman Robert E. Linton Gregory White Eric Goldstein Robert and Catherine Beyer Ira A. Lipman David Yandry Maureen V. Gorman Frank and Carol Biondi, Jr. Los Angeles Lakers Don Yannias Alan C. Greenberg BlackRock Financial Management Laurence and Karen Mandelbaum Zapolin Transactional Ventures, Inc. Mr. and Mrs. Kenneth B. Hamlet Jim & Diane Blair Charitable Foundation Bernard Marcus Clay W. Hamlin III Dan Blumenthal Margaritaville Holdings, LLC Friends John J. Hannan Boston Red Sox Michael Marek ($25,000 - $49,999) Reed and Nan Harman Jerry Brassfield John E. McCaw Anonymous (1) William Hartnett Shann Brassfield Joseph and Anne McCann Don Ackerman Ralph and Kay Hemingway Gresham T. Brebach, Jr. Richard McKenzie, Jr. Neale M. Albert, Esq. John and Susan Hess Steven A. Burd Barry Meyer Norman E. Alexander Samuel J. Heyman Frank Caufield Millennium Pharmaceuticals, Inc. Allchin Foundation Kenneth and Janet Himmel Ray and Patti Chambers Edward J. Minskoff Arby’s Charlie J. Horky Alfred and Kathryn Checchi Michael Minikes Frank J. Arcella Charles and Barbara Hurwitz Chicago White Sox Morongo Band of Mission Indians Matthew Arcella The Iacocca Foundation Marshall and Maureen Cogan Nat. Amer. Right Fund Roland E. Arnall Internet Real Estate Group, LLC Jerry and Adrianne Cohen Movado Group, Inc. Ashton Distributors, Inc. Vincent Iorio Robert and Beverly Cohen Family Angelo and Phyllis Mozilo AstraZeneca IRI Golf Management, LP Foundation Ken Nees Robert Bales Steve and Ellen Jackson James H. Coleman Neiman Marcus Direct Jude T. Barbera, M.D. Stanley R. Jaffe Countrywide Credit Industries Netjets Aviation, Inc. David W. Bash, Ph.D. and David S. Howe and Charlene Wang Howard Cox Aviv Nevo Judy Oliver-Bash, Ph.D. Gerald Katell Credit Suisse First Boston Corporation L. M. Newman Family Foundation Arthur Becker and Vera Wang Stephen and Marina Kaufman Dendreon Corporation New York Mets Foundation, Inc. Robert A. Belfer The Fritz and Adelaide Kauffman Detroit Tigers Jon Otto Art H. Bilger Foundation, Inc. Michael D. Dingman Palermo Ravich Family Foundation Les and Sheri Biller KB Home Ty and Fran Durekas The Palin Family Foundation, Inc. Bobby Blair J. Christopher Kennedy Robert and Tricia Earl Jim Pattison Bloomberg L.P. Michael Klein Bruce Eichner Ethan Penner Bluefish Concierge, Inc. Henry R. Kravis David J. Epstein The Picower Foundation Salvatore and Alison Bommarito Benjamin V. and Linda Lambert Faith, Love, Hope, Win Foundation Chris Prezioso David Booth Bill Lane, Jr. William B. Finneran Pritzker Foundation Tony Borhani Jeffrey & Nancy Lane Foundation, Inc. First Data Western Union Foundation Martin and Patricia Raynes Denis A. Bovin Gerrity Lansing and The Safeway Foundation The Republic of Tea The Braka Philanthropic Foundation Bennett and Jerri Lebow David and Judith Fleischer Richard S. Ressler Harry M. Brittenham, Esq. Steve Lehman Paul M. Fleming Tony Ressler and Jamie Gertz Coco Brown John S. Levy Forester Family Foundation Meshulam Riklis Thomas and Jo Anne Bruno Linder Charitable Remainder Unitrust Theodore J. Forstmann The Riordan Foundation John M. Bryan Joseph Rob Link Freeport-McMoRan Foundation George R. Roberts Brian P. Burns Joe Lumarda Michael Frey Allan V. Rose Dick and Lisa Cashin Susan E. Lynch William and Susan Gross Andrew M. Rosenfield Andrew S. Clare Gene E. Lynn Arthur J. Gallagher & Co. Pat and E. John Rosenwald Brian and Denise Cobb Donald and Hilda Lytton Gantcher Family Philanthropic Fund The Rose Foundation Gregory and Monica Coleman David S. Mack Jeffrey D. Gargiulo Eric Rothfeld David and Courtney Corleto Fredric Mack Arthur and Linda Gelb Peter H. Rothschild Lester and Renee Crown Harvey Mackay Jay Geldmacher Steven and Daryl Roth Edgar and Elissa Cullman Bernard L. Madoff Global Fitness Holdings, LLC Mike Ryan Ian M. Cumming Stanley and Pamela Maron Henry and Arline Gluck Ronald Salkow Robert and Kelly Day Howard and Nancy Marks Jeremy P. Goldberg salesforce.com/foundation Celine Dion Foundation Robert and Joan Masterson Richard and Marcia Goldberg Allen B. Schwartz Los Angeles Dodgers Harold Matzner Stanley P. Gold Richard J. Schmeelk Mark Donnelly Michael McKeever
9 Progress Report
Dennis Mehiel Supporters Donald and Nancy Carter The Diane and Elliot Feuerstein Fund Jerome Meislin ($10,000 - $24,999) Edwin P. Carter of the Jewish Community Foundation Merck and Co., Inc. Anonymous (1) Caymus Vinyards Mark Finerman Herman and Susan Merinoff David and Kay Aaker Marx L. Cazenave II Gerald B. Finneran Harold M. Messmer, Jr. Paul Abecassis Tom Celani Richard Fisher Theodore N. Miller S. Daniel Abraham Cell Genesys, Inc. Jerome and Anne Fisher Lee and Sylvie Millstein Abramson Family Foundation, Inc. Centocor, Inc. Larry and Kathleen Fisher Minnesota Twins Joseph P. Adams, Jr. Irwin Chafetz Lester and Gwen Fisher James F. Moore Sheldon Adelson Charity Folks, Inc. Joseph Flom Robert E. Morrow Larry Alleto Chartwell Foundation Steven T. Florio Mark E. Mortimer Bruce and Elvin Ambler Linda Chen Florida Marlins Stuart W. Moselman Lee W. Ang Peter Chernin Lynn Forester Miles Nadal Judd Apatow Allen and Jill Chozen Michael G. Foster, Jr. Joseph Neubauer Michael F. Armstrong Chubb Federal Insurance Company Foxsports.com John Nickoll Arnon Milchan Citigroup Lionel Frais T. D. O’Connell Michael F. Ashby Clarion Operating LLC Paul Fribourg Chris K. Olander Atlanta Braves Foundation, Inc. The Clark Charitable Foundation Friedman Family Foundation Pierre and Pam Omidyar Mark and Debbie Attanasio The Clinton Family Foundation Josh S. Friedman Larry R. Palmer, CEP, CTP Jerry Auerbach Coca-Cola Co. Peter Fudge William J. Polvino, M.D. Autism Speaks, Inc. Harold K. Cohen Jeffrey Furman John and Laura Pomerantz Abraham Azoulay Mitchell H. Cohen Frederick and Peggy Furth Portland Bolt & Manufacturing Baby Togs Jim and Marcia Colbert Ronald H. Galowich Post Advisory Group Bacon LLC Commerce Bank, North, N.A. Michael and Lynn Garvey Anthony & Jeanne Pritzker Family Dan Baldwin Jimmy and Patti Connors General Nutrition Centers Foundation Martin and Dorothy Bandier John and Constance Arie Genger Royce G. Pulliam Jeffrey C. and Lori Barbakow Nancy and James Cook Russell Geyser Alan Quasha Sol Barer The David and Sheila Cornstein The Honorable Rudolph W. Giuliani Mark Quigley F. Harlan Batrus Foundation Guilford and Diane Glazer Richard E. Rainwater William P. Beatson, Jr. Jack B. Corwin Alan and Marlene Gleicher Ramblewood Country Club Richard I. Beattie Robert H. Cosgriff Seth Glickenhaus Bill R. Roberts Warren Beatty Terry Cosgrove Russell D. Goldsmith Bob Roberts Candice Beaumont The Gerald and Daphna Cramer Family Colin Goddard, Ph.D. Richard and Barbara Rosenberg Eric D. Becker Foundation Bradley and Sunny Goldberg Stan and Patti Rosenfeld Dr. Gary S. Becker Alberto Cribiore Michael A. Goldberg Country Club of Roswell Michael Becker Robert and Mary Ann Cross R&M Goldberg Family Foundation Round Hill Country Club Mitch Becker Cuba Club Andy Goldfarb Andrew Ruotolo Allen J. Beeber Chip Cushman R. Anthony Goldman Barry L. Rupp William J. Bell Theodore Cutler Michael Goldstein Alvin and Marilyn Rush Lee and Susan Benton Cytogen Corporation The Golfworks Peter M. Sacerdote Foundation Anthony Bergamo, Esq. Dabney/Resnick Imperial Litto Gomez Ronald Saks Eric L. Berg John Daly Bennett and Meg Goodman David Sambol Elliott H. Berger Darling Family Fund The Gordon Family Foundation The Mara and Ricky Sandler Foundation Jeff Berg John R. and Kiendl Dauphinot Gordon Edward and Cheryl Gordon Fund Richard and Margaret Santulli Daniel G. Bergstein The John and Kiendl Gordon J. Morton Davis John H. Schnatter The Judy and Howard Berkowitz Berry Gordy, Jr. Michael and Paola Schulhof Foundation Michel De Beaumont Steve Lawrence and Eydie Gorme Irving Schneider David Berkoski Joseph J. Dempsey Abraham D. Gosman Brett T. Setzer Allen J. Bernstein Cosmo DeNicola Fredric Gould David and Fela Shapell Fred B. Bialek Donald J. Deutsch John P. Gould Mace and Jan Siegel The Black Family Charitable Deutsche Bank Laurence Graff David and Lynn Silfen Foundation, Inc. Terry and Marilyn Diamond Mark Grant Fred L. Smith The Stanley & Joyce Black Family Dietz & Watson Foundation Madison and Susan Graves Irwin and Lorri Spiegel Foundation Richard DiMeola George D. Grayson St. Louis Cardinals Harvey Blau Dinan Family Foundation George & Reva Graziadio Foundation Fred and Sharon Stein Charles X. Block Don King Productions, Inc. Steven and Dorothea Green Steinberg Family Fund, Inc. Dennis Block Donaldson, Lufkin & Jenrette Gary and Sandra Grimes Spencer Stokes Bloomberg Financial Markets Co. Carl Doumani Grizzard Family Foundation, Inc Stricklin Account of Fidelity Bonita Bay Community Milton H. Dresner Foundation, Inc. Julie Groshens Charitable Gift Fund Burton Borman David H. Dreyfuss Michael S. Gross Burt and Mary Sugarman Albert R. Boscov Dunwoody Country Club Haarlow Family Charitable Foundation Jim Tarlton G. Michael Boswell Joseph J. Dvorak, Jr. Roger S. Haber Willia Thompson Reggie Bowerman Alvin Dworman Kerry and Kelly Hagen James Tisch Steve Braverman Eastdil Realty, Inc. David and Leslie Hahn Bruce E. and Robbi S. Toll Foundation Bernard and Judy Briskin Charles Edelstein Brian L. Halla Marc and Mindy Utay Broad Street Productions Stephen Einhorn James A. Harmon Peter Vegso Brooklyn Hospital Center Steve Eiseman Richard J. Harrington Michael and Laura Venerable Gloria S. Browning David F. Eisner Mel Harris Linda J. Wachner Harry J. Brown Foundation Roger A. Enrico William B. Harrison, Jr. Charles J. Wagner John M. Bryan Family Fund Mike Ensign Richard C. Hartnack Samuel Waksal Bryanston Group, Inc. The Daniel J. Epstein Fund of the Albert and Irene Hartog Ira Walker Kurt W. Butenhoff Jewish Community Foundation Richard J. Heckmann Elmer Ward Bernie F. Butler Jeff Epstein Andrew L. Heiskell Michael and Jill Weinstein Michael Butler Evergreen Foundation Jane Heller Stephen and Phyllis West Canyon Partners Jonathan D. Farkas Jerry Hennessy Christopher and Kristine Williams Cardean Learning Federated Department Stores Foundation Lawrence Herbert Henry Wilf Cardinals Care Brad Felenstein Sam Herzberg Rick Wooley Michael Caridi Robert M. Fell Andrew R. Heyer Don Zacharia Liam Carlos James and Alise Ferency Rick Hill Johnny Carson Mike Ferry Douglas Hirsch and Holly Ander The Armin & Esther Hirsch Foundation
10 Progress Report
Joni Hirsch Blackman Julius and Miriam Lesner David Pecker Martin Selig H.J. Heinz Company Frederick N. Levinger Arthur Penn Mike Shad HLT Prostate Cancer Fund Frances and Jack Levy Foundation Pensions 2000 Michael Shapiro Beth Hollfelder Richard Levy Leonard C. Perham Shearman & Sterling Butch Holmes Loida N. Lewis Phillips-Van Heusen Foundation, Inc. Howard Shecter Jane Holzer Robert Lienau Phoenix Home Life Mutual Mark Shenkman Homayoun Homampour Steven Lipman Insurance Company Robert D. Shipp Home Box Office Michael D. London Elizabeth Pinsonault Boaz Shonfeld Steven and Cathy Hooper David B. Lowry Albert and Jeanine Pirro Walter Shorenstein Houston Astros LS Management Michael A. Pitino Stan Shuster D. E. Brice Howe Rufus and Patricia Lumry Mack Pogue Stanley J. Sidel H. S. Hoffman Robert G. Lusk Carl and Eloise Pohlad Family Foundation Sanford C. Sigoloff Helmut Huber Richard Mack The Poses Family Foundation Jay B Silverman Michael Huffington Macy’s Steve Posner Mark J. Simon Gene Humphrey John Magliocco Maury Povich and Connie Chung Thomas M. Simms Fred C. Hutchinson Cancer Research Peter A. Magowan William L. Price Ted Simpkins Center Mel Mannion Wayne Prim, Jr. Sirens Society Michael Hyatt Mandalay Resort Group Michael J. Price Sanford Sirulnick Royce Imhoff Mandelbaum Foundation Prometheus International, Inc. John and Cindy Sites International Financiers, Inc. Alan and Barbara Mandelbaum Ed W. Rabin Charles B. Slack Invemed Associates, LLC Stuart Manheim, CPA Harvey and Pauline Radler Alan B. Slifka Ironman Motivations Stephen J. Marcus Sheri and Marc Rapaport Fund Lynn Smiledge Jack and Ginger, LLC Mariners Care of the Jewish Cmmnty Fndtn Smithburg Family Foundation Jacks Broken Open Howard and Stacy Marks Mr. and Mrs. Joseph Rascoff John F. Smith, Jr. Sheldon Jacobs Nancy Marks Bruce Ratner Matthew and Tracy Smith Herb W. Jacobs Marvin Engineering Co., Inc. Michael Ratner Orin Smith Nathan P. Jacobs Maverick Capital Foundation Ravich Revocable Trust Snyder Weiner Weltchek & Vogelstein Ron Jacoby Kenneth Mazik Randolph and Lindsey Read Marilyn Sobel Robert M. Jaffe Larry Mazzola John S. Reed Bruce Sokoloff Leonard R. Jaskol Michael and Kristy McChesney Richard and Marget Reneberg Bob Solomon The JCT Foundation Les G. McCraw, Jr. W. Brent and Brenda Rice Warren J. Spector Christopher M. Jeffries MCI WorldCom Foundation Denise Rich Allison Speer Michael and Linda Jesselson Thomas J. McKearn Robin Richards Jerry Speyer Johnson Bank Miss Kara McKinley James S. Riepe Family Foundation Lawrence Spira, M.D. Clark A. Johnson J. P. McManus Richard A. Rigg The Starr Foundation Allen N. Jones James A. McRae Harold W. Ripps Joseph Stein Ellis B. Jones Medco Containment Co Richard K. Robbins Jeffrey Steiner Glenn R. Jones Keith Meister Brian L. Roberts Irving Stenn, Jr. The Joseph and Ida Foundation Inc. Todd Meister Kenn Roberts Michael Strauss Mitch Julis Prakash Melwani Ralph J. Roberts Lawrence Sheldon Stroll David G. Kabiller, CFA Milwaukee Brewers Thomas and Mary Alice Roberts Melanie Sturm John Kahrhoff Memorial Golf Larry A. Mizel James D. Robinson III Marianne Sufrin Kansas City Royals Robert Michael Mondavi Rodney Strong Vineyards Sanford and Charna Sugar Harold Sanford Kant, Esq. Charles K. Monfort Gerald Ronson Sunbelt Beverage Company, LLC Abraham Kaplan Foundation Eugene Monkarsh Allison Rosen Katharyn Swintek Donna Karan Jim Mooney Paul and Catherine Rosenberger Tag Associates, LLC Scott G. Kasen David Moore Fredric D. Rosen Roberta R. Tanenbaum Peter M. Kash Pete Moore Betsy Ross Jeremiah and Nonie Tarr Howard and Susan Kaskel Jerry Moss Byron Roth Stanley G. Tate David and Silvana Kay Wayne Mueller James Rothstein Fredricka Taubitz Joshua and Joia Kazam Donald R. Mullen Michel Roux Ian Ross Taylor Dean C. Kehler Peter Mullin James Russell Robert Taylor Solomon Kerzner Bill Mundell Kenneth and Dina Russell Douglas P. Teitelbaum Gregory F. Kiernan Hilary Musser Edward B. Rust, Jr. Anthony Terlato Brian King Warren V. Musser Stephen Ruzow Charles and Adele Thurnher Michael G. King, Jr. Naples Drive for the Cure Steve Sanak Andrew H. and Ann Tisch Kirkland & Ellis Foundation The Nash Family Foundation Richard Sandor Daniel and Bonnie Tisch Joel Kirschbaum Menasche M. Nass Michael Sandorffy Steven H. Tishman Daniel J. Kleiman David Nazarian Andrew Scheinman Dennis A. Tito Calvin Klein Marty Nealon Sylvan Schefler Pier Luigi Tolaini James W. Klein Rooney Nelson David Schneider John T. Toland Michael and Patricia Klowden New England Financial Raymond D. Schoenbaum Richard P. Torykian, Sr. KML Golf, LLC New Jersey Basketball, LLC Lewis M. Schott Jesse I. Treu Harold and Shirley Kobliner Wayne and Kathleen Newton Joan and Paul S. Schreiber Philanthropic Prabhakar Tripuraneni, M.D., FACR Jeff Koffman NFL Charities Fund of the Jewish Communal Fund The Trump Organization KPMG, LLC Dr. Perry Nisen, M.D., Ph.D. Ian Schrager Tudor Investment Corporation Jules B. Kroll Northern California District Council Schultz Family Foundation Robb & Elizabeth Tyler Foundation, Inc. A. B. Krongard of Laborers David K. Schulhof Valquip Corporation Mark Kurland Novacea, Inc. Marvin H. Schur The C. George Van Kampen Foundation Herbert and Edyth Kurz Marlene Nusbaum Ted Schwartz Karen van Nouhuys Lachman Family Foundation Oakland Athletics Charles and Helen Schwab Varhegyi Foundation L’Acquisition Corporation Cindy K. Olson Schwartz, Kales Accountancy Corp. Mary T. Venable Ken Langone Peter Busch Orthwein Alan D. Schwartz The Vons Companies Charitable Latham & Watkins Gregory J. and Mary V. Pacelli Barry K. Schwartz Family Foundation Foundation, Inc. Leonard and Evelyn Lauder Chuck Palombini Charles Scott Rosemary Vrablic William P. Lauder Marvin Parsons Tony Scotti Don Vultaggio Norman Lear Alan Patricof Russell Scott, Jr. Shirlene A. Wainer Lederman Family Foundation Norman J. Pattiz Sebastiani Vineyards, Inc. William and Claudia Walters Don and Rita Lee Paul, Weiss, Rifkind, Wharton & Security Life Inc. Group Kenneth Wang Stephen R. Leibowitz Garrison, LLP Ivan G. Seidenberg William and Sharon Ward
11 Progress Report
Tom Watkins Marc Blackman Robert Dodson Jesse Halperin Scott Watt Robert S. Blank Drexel University Fred Hameetman Robert F. Weis Michael and Nina Blechman Daniel A. Duc Mark S. Handler Melvyn I. Weiss Tim Blixseth Duch Family Fund of the Community Mark S. Hanson Morris Weissman James A. Block Foundation of New Jersey Martin Aaron Harmon Dr. Herbert A. Wertheim Ron Boeddeker Raymond Duncan Gilbert W. Harrison Whittemore Family Foundation Franklin Otis Booth, Jr. J. C. Earle Family Fund Lauren M. Hartman Ralph and Wendy Whitworth Kurt T. Borowsky Walter Eberstadt Edward J. Hawie Arthur Wiener Richard Boughner Spencer F. Eccles Kenneth and Kathryn Henderson Andrew Wise Thomas S. Bowman David B. Edelson Thomas S. Henderson and Sally S. Alexander J. Witherill Larry Bowman Daniel D. Ederer Henderson Foundation Fred Wolf Leonard Boxer Maurits E. Edersheim Arthur Hershaft Douglas J. Wood Thomas Breitling Anders B. Eklov Michael B. Hershey C. Tal Wooten, Jr. Stephen M. Brett Richard and Gail Elden Edward and Gaye Hewson Young Presidents Organization Pete Briger Elmwood Country Club The Annette Heyman Foundation Inc. Los Angeles Chapter Pam Brill Endocare, Inc. David Hicks Gerard Yvernault Nancy Brinker Mr. and Mrs. Alfred Engelberg Roderick Hills Louis G. Zachary, Jr. Gary Briskman Robert Englander Hilton Hotels Corporation Harriet Zaretsky Edward Brodsky Yan Erlikh Leslie Wohlhan Himmel Jeffrey Dunston Zients Jeffrey P. Brown Aaron R. Eshman Peter A. Hochfelder Roy Zuckerberg Richard A. Brown Linda Evangelista Robert W. Hoke Robert A. Zummo Susan Mader Brown William F. Evans Richard Scott Hollander Sergio Zyman Christopher H. Browne Eugene and Sallyann Fama Mark Holowesko Richard C. Browne Samer Farah, M.D. Vincent Horcasitas Contributors C. Kenneth Brumit Andrew Farkas Gerald Horowitz ($5,000 - $9,999) Marc R. Brutten John Farnsworth John and Sandra Horvitz Anonymous (2) Deborah L. Burger, Inc. Michael S. Fawer Thomas J. Howa Robert J. Abt Alan A. Burgess Dr. Jeffrey P. Feingold Joe Howe The Adler Family Foundation, Inc. William and Elizabeth Burroughs Stanley M. Feingold HSK Funding Advance Shared Services Center Jack Burstein Irving Feintech Harry and Elsie Huber AIM Management Group Richard Byrd Frank and Victoria Fertitta Wayne Huizenga Alvin R. Albe, Jr. Roger and Mary Campbell Gregory Fischbach James Husband Ellis J. Alden Phil Caputo Stephen B. Fiverson George Hutchinson Richard L. Alderson Ronald G. Carley Dennis Flatt Lee Iacocca R. Jack and Beulah Alexander William M. Carson Robert Forbes Arthur I. Indursky Donald and June Alford Frank L. Cassidy, Jr. Sam Forman Institute for Health & Productivity Lawrence B. Alletto Matthew J. Celozzi II, Ph.D. Gayle Devers Fortune Management Allied Beverage Group, LLC Chajet Family Foundation David Foster Hale S. Irwin Arthur G. Altschul, Jr. Michael J. Charles William C. Foster Jeremy Jacobs Ellsworth C. Alvord III Charlesworth Family Limited Partner Michael F. Frankel Max Javit Richard W. Alvord Gary Charlesworth Albert Fried, Jr. Gordon W. Jenkins American Endowment Foundation Sophie Chen, Ph.D. Joel Friedland Charles Jennings Ameripoint Foundation Bernd Chorengel Robert and Ann Fromer Daryl L. Jesperson John Angelo Clarium Capital Management, LLC Roy Furman Jewish Federation of Greater Phoenix Tom Armstrong Greg Clark Tom W. Gamel JFD / MJD Golf Open Arris Interactive L.L.C. John H. Claster Howard L. and Judie Ganek James and Lorene Jimmerson Phillip Asherian Bert Cohen Philanthropic Fund Alastair J. Johnston Michael Ashkin Joseph M. Cohen Lloyd Garver Wayne D. Jorgenson Sherrell Aston Karen B. Cohen Foundation Inc Frank Gehry The J.P. Morgan Chase Foundation Robert Atherton Richard D. Cohen Alan Gelband Jay Kaiser Victor K. Atkins The Betsy and Alan Cohn Foundation, Inc. Genentech, Inc. Kaiser Permanente Aureon Laboratories, Inc. Victor A. Cohn Georgetown Tobacco & Pipe Stores, Inc. Peter S. Kalikow Rick G. Avare Collington Transportation Golf Outing S. William Gersten Thomas J. Kalinske Bacardi Limited William S. Comanor, Ph.D. Michael F. Gilligan, Jr. Bruce and Jeanie Kaminsky Roland and Beverly Bacci Community Foundation of Tom Giovanelli The Kandell Fund David and Michelle Bach Greater Memphis David H. Glaser Walter Karabian Baltimore Orioles Kerby and Judith Confer GNC Eric P. Karros Jeffrey and Pamela Balton Connecticut MSBL Arthur M. Goldberg Stanley Katz The Bandier Family Foundation Michelle A. Connelly Howard Goldenson Stephen Katz Scott P. Barasch Elaine Terner Cooper Steve A. Goldfarb George Kaufman Judy Bardugo and Harve H. Mossawir, Jr. James C. Cook Dr. Kenneth N. Goldman Ivan Kaufman Janice Barney John Cooper, Jr. The Golush Family Charitable Fund Ronald S. Kaufman The Barrack Foundation Stephen A. Cooper, DMD, Ph.D. of the Vanguard Charitable Ilan and Linda Kaufthal Tyler Barth Peter Coors Endowment Program Richard and Suzanne Kayne Michael J. Batza, Jr. The Copses Family Foundation Jan Goodman Gershon Kekst Charles T. Bauer Fred Corrado Bradford S. Goodwin Donald H. Keltner Ted Baum Cresa Partners Richard Goodwin Ken Roberts Company David I. Bavar Richard Crisman Todd Goodwin Keys Foundation Lee Beattie Gregory Cuneo Jerome S. Gore Kibble & Prentice Jack M. Beaven Cunningham Security Systems Jim Grau Kidz, LLC Alan T. Beimfohr Cushman & Wakefield Charles H. Greenberg Jerry King Joseph and Louise Bellace Lucio Dallla and Marta Gasperina Mark Greenhill Lila Kingsley Bradley Bell Billy Davis, Jr. Robert W. Greenman, Jr. Burton Koffman John Bendheim Marion J. Davis, Jr. Robert Grossman Eugene Kohn Philip J. Bergan Peter and Julie Dawson Howard R. Gurvitch Oswaldo Kosta Susan B. Bergan Ed DeBartolo, Jr. Blair Haarlow Roger and Lorraiine Kotch Martin S. Berger Delaware North Companies, Inc. William and Evangeline Haarlow Robert Kraft Anthony J. Bettencourt Delcal Enterprises, Inc. Lynn M. Haff Norman D. Kurtz William C. Bevins Jerry Della Femina John Hagestad John and Kay Kyle Les Bider Dodger Dream Foundation, Inc. Hall Dickler Kent Goldstein & Wood, LLP Laborers’ International Union-Local 270
12 Progress Report
Laborers’ International Union of El David A. Miller Robert E. Racicot James Soules Monte-Local 1082 Laura and Michael Miller Steve Rader Southern Wine & Spirits of Nevada, Inc. Laborers’ International Union of N. Mary Sullivan and Sherman Miller, IV Raley’s Gold Rush Classic Jerry and Emily Spiegel Family America-Local 300 Honorable Robert Joseph Miller Max Ramberg Foundation, The LA-CO Industries, Inc. Peter H. Mills Scott Gregg Rechler Larry Spitcaufsky Linwood A. Lacy Phillip S. Mittelman Donald Rechler Richard and Ellie Sprague Fred S. Lafer MLB.com Joseph P. Riccardo Frank P. Stagen Robert F. Lampe, Jr. Alan Mnuchin Blair & Kristin Richardson Foundation Stak Design, Inc. Sprenger Lang Foundation Arthur and Patricia Modell Richard B. Fisher Starbucks Coffee Company Ira N. Langsan & Lillian Langsan James J. Moglia Ritz-Carlton John Stark Philanthropic Fund David Moore Ritz-Carlton Boston Starkey Sports Consulting, LLC Robert Larner, M.D. Raymond Moore Lee P. Rizzuto The Laura Steinberg Tisch Martin and Sheila Lasky Morongo Band of Mission Indians Linda G. Robinson Foundation, Inc. Ronald Lauder William S. Morris III Sam Robson Steven E. Stern Lynn M. Leany Morton’s Restaurant Group Iber Rodriguez The Stone Family Fund Frank Leanza Paul Motenko Sig Rogich Gary Stoneburner Ken Leese Charles H. Mott Jeffrey Rosenthal Bonnie and Tom Strauss Charles E. Leonard III Joseph M. Murphy Stephen M. Ross Chris Stuhmer Steve Leonard Alan C. Myers Paul R. Del Rossi Fred and Judith Sullivan Margaret Lesher Douglas P. Nation Gordon Roth Mary M. Sullivan John and Betty Levin NBA Properties, Inc. Edward F. Rover Suns Legacy Partners, LLC Neil Levine Renato Negrin Richard and Amy Ruben Dennis A. Suskind Dan and Stacey Levitan Lee S. Neibart Howard Rubin Don Swirnow David Levy Craig T. Nelson Mariano A. Rubino S. Jerome and Judith Tamkin Laurence R. Levy Mary-Rose Nelson Denny Ryerson Rica F. Tarnoff Edward Lewis Nestle Waters North America, Inc. Thomas L. Safran Janie C. Tarter The Liberal Do-Gooder Foundation Blake Lee Neubauer, Ph.D. Max and Janet Salter Walter D. Tearse David Liebowitz Shilom Neuman San Diego Padres Vincent Tese Sio Lindner Chuck Nicolette, M.D. Allan C. Sanders Chuck B. Thornton, Jr. Samuel S. Lionel Niebaum-Coppola Estate Winery Theodore and Alison Sands Steve Tino Jeffrey and Susan Liss James B. Nish Sandy Spring Bank Tom Tisch The Litwin Foundation, Inc. Robert Noelke Patrick Savin TJH The Loa Productions, Inc. Douglas and Nancy Norberg Saybrook Tax-Exempt Advisors, LLC Thomas Tonko The Arthur Loeb Foundation Greg Norman Randall H. Scarlett Stanley S. Trotman, Jr. John L. Loeb, Jr. NorthAtlanta National Bank Al Scheid Cecily Truett Shumer Lonoff Nsuh Foundation Schmertz Company, Inc Mark Truitt Lords Valley Country Club, Inc. Obermeyer Asset Management Company Alfons J. Schmitt Jeffrey H. Tucker Bob Lorsch James T. O’Brien David M. Schoenthal Turner Broadcasting System, Inc. Douglas and Nancy Lowe The October Foundation for Kids Marvin I. Schotland UBS AG Lyncar Enterprises, Inc. Morris Offit The Lewis Schott Foundation Peter V. Ueberroth Gordon Maahs John O’Hurley Robert Schulman William D. Unger Harry Macklowe Marvin Olshan Michael and Lora Schultz United Jewish Foundation of John Magnier Shepard Osherow Gerald M. Schuster Metropolitan Detroit Anthony J. Magro Dan Otter Homer R. Schwartz United Way of Greater Los Angeles Brian A. Maki The Estate of Corbin Page Governor Arnold Schwarzenegger and Tom Unterman Idelisse Malave Donald P. Pakosh Mrs. Maria Shriver Michael J. Urfirer Judd Malkin Norm Pappas Lisa White Schweitzer Neil G. Van Luven Shareef Malnik Partners Marketing Group Peter W. Schweitzer Basil K. Vasiliou George J. Maloof Rafael Pastor Spencer and Jacqueline Segura The Daniel Veloric Foundation Bernard A. Marden E.H. Patterson Dr. Michael E. Seiff Velos Medical Informatics, Inc. Mark Asset Management Corporation Frances B. Paulsen Richard M. Seigel Mary E. Venable Morris Mark Randall Eric Paulson Michael S. Shannon Benjamin A. Wade Ken Martin Clay Pecorin Carl and Ruth Shapiro Family Foundation Robert and Judy Waller Kim Martindale Elsie Pecorin, DBA Robert F. Shapiro David E. Walters Elliott Masie David R. Pedowitz Thomas and Madeleine Sherak John Walton Norman and Joanne Matthews Robert F. Pence Pam Shriver Fund of the Baltimore Jack L. Warner Giacomo Mattoli James C. Pendergast Community Foundation Roger Weber Caryn Mautner Mark Perlbinder Herbert J. Siegel Raymond J. Weis Thomas and Musa Mayer Charles Persico William Siegel Robert Weiss James N. McCoy Foundation James L. Peters Adrianne W. Silver Jay Weitzman Richard E. McCready Foundation Fund of Robert E. Petersen Richard Silverman Miles D. White the Baltimore Community Foundation Pharmaceutical Research and Ronald A. Simms Jeffrey S. Wilks Liam E. McGee Manufacturers of America David Simon Gary L. Wilson John S. McIlwain Gerald Porter Dick Simon Daniel P. Wimsatt Laureston and Barbara McLellan Timothy N. Poster Mimi Simoneaux Wolff Family Foundation Don McNamara Rick Powell Plum and Jonathan Simons Moira Wolofsky Robert J. McNulty Ed Prager James D. Sinegal Working Assets Rolf Meijer-Werner Arlen I. Prentice Van Skilling Rodney A. Wray The Melville Foundation Wayne Prim, Sr. Joel E. Smilow Bud Yorkin Merrill Lynch & Co. Foundation, Inc. Edward Probyn Gordon Smith Young Presidents Organization Leroy Merritt Bob Pryt Jeff N. Smith Rebel Chapter The Morris and Helen Messing John A. Ptak Arnold Snider Stan Zicklin Foundation Kjell H. Qvale Steve Snyder Ron Zimmerman Dwayne Middleton Mark Rachesky Mr. and Mrs. Stuart M. Solomon
Every effort has been made to ensure completeness and accuracy of this list. If errors or omissions exist, please accept our apologies and call 800.757.CURE (2873). Thank you.
13 Progress Report Appeal for Support
Dear Friend:
In the past fifteen years, deaths from prostate cancer have dropped, research has sped forward and hope has continued to soar. On behalf of patients, families, caretakers and the science that serves them: Thank you. These continuing successes would be unsustainable without your ongoing support.
Your investment in the Prostate Cancer Foundation (PCF) is wisely deployed. Since 1993, virtually every important discovery in this battle has been facilitated by PCF funding or coordination. Moreover, every dollar you contribute to the PCF is multiplied 20 to 30 times; our activities set into motion a ripple that spurs research at government, private and charitable institutions and, in effect, leverages the millions of dollars we raise into billions.
You also help us build a collaborative community. Fifteen years ago, prostate-cancer researchers had no vantage point to comprehend the full scope of others’ efforts. Today, no other organization has a more comprehensive view of the full prostate-cancer landscape and its most-promising research than the PCF.
Your continued generosity is more important than ever. The need is especially urgent now, with pressures on federal budgets causing not simply a flattening of research funding from the National Institutes of Health but, in adjusted dollars, an alarming decline. This decline is a grave threat to the momentum we’ve built.
Your support is important to us. We ask that you act now.
With deepest gratitude,
Jonathan Simons, MD President and Chief Executive Officer David H. Koch Chair
14 Progress Report donation opportunities
The Prostate Cancer Foundation welcomes gifts of cash, securities, non-cash assets and gifts by will or living trust. We also welcome contributions made in memory, in tribute or in honor of friends or loved ones.
Donations Other Gift Suggestions
Please mail your check to: n Assets or property including appreciated stock and real estate. Prostate Cancer Foundation
1250 Fourth Street n Bequest – include a gift to the PCF in your will. Santa Monica, CA 90401 n name the PCF as the primary or contingent To make an online contribution, please visit our beneficiary on a life insurance policy. website: www.pcf.org n rollover funds from your IRA as a gift to the If you prefer, you can make a donation by phone by PCF and avoid all tax on the rollover (valid through calling toll-free (800) 757-CURE (2873). December 31, 2008 and applies to those 70-1/2 years and older). Memorial or Tribute Gifts More information: www.pcf.org n Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others. n Make a memorial or tribute gift and the PCF will send an acknowledgement card to the family or honoree.
15 Prostate cancer foundation Statements of Financial Position
Years Ended December 31 2007 2006
Assets Current assets: Cash and cash equivalents $ 21,275,262 $ 12,802,192 Pledges receivable 6,442,212 9,190,210 Marketable securities 52,868 29,384 Prepaid expenses 59,216 62,401 Other receivables 50,564 110,598 Total current assets 27,880,122 22,194,785 Furniture, equipment and improvements: Furniture and fixtures 37,180 37,180 Office equipment 110,574 166,062 Leasehold improvements 246,891 246,891 Computer Software 325,280 249,671 719,925 699,804 Less accumulated depreciation (542,457) (605,536) 177,468 94,268 Long-term pledges receivable 1,236,542 1,540,795 Total assets $ 29,294,132 $ 23,829,848
Liabilities and net assets Accounts payable $ 366,535 $ 186,831 Accrued liabilities 1,546,860 1,371,664 Research awards payable 8,650,000 13,531,870 Total liabilities 10,563,395 15,090,365 Unrestricted net assets 18,730,737 8,739,483 Total liabilities and net assets $ 29,294,132 $ 23,829,848
16 Prostate cancer foundation Statements of Activities
Years Ended December 31 2007 2006
Support and revenues: Donations $ 34,773,813 $ 27,858,493 Net realized and unrealized (loss) gain on investments (1,578) (9,076) Interest and other income 624,047 339,537 Total support and revenues 35,396,282 28,188,954 Program services: Research grants, association awards and donations 14,274,150 15, 297,393 Scientific conferences 2,420,640 3,045,916 Public awareness and advocacy expense 1,560,191 1,897,846 Total program services 18,254,981 20,241,155 General and administrative expenses 2,420,921 3,133,141 Fund-raising expenses 4,729,126 3,931,397 Total expenditures 25,405,028 27,305,693 Change in net assets 9,991,254 883,261 Net assets at beginning of year 8,739,483 7,856,222 Net assets at end of year $ 18,730,737 $ 8,739,483
17 Prostate cancer foundation Statements of Cash Flows
Years Ended December 31 2007 2006
Operating activities Change in net assets $ 9,991,254 $ 883,261 Adjustments to reconcile change in net assets to net cash provided by operating activities: Depreciation and amortization 63,082 130,790 Donation of marketable securities ( 227,158 ) (1,368,639) Net realized and unrealized gain (loss) on investments 1,578 (9,076) Proceeds from sales of marketable securities 225,580 1,782,748 Changes in operating assets and liabilities: Pledges receivable 3,052,251 (36,750) Marketable securities (23,484) – Prepaid expenses 3,185 663 Other receivables 60,034 408,321 Accounts payable 179,704 ( 695,165) Accrued liabilities 175,196 (174,864) Research awards payable (4,881,870) 4,301,870 Net cash provided by operating activities 8,619,352 5,223,159
Investing activities Purchase of furniture, equipment and improvements (146,282) (10,618) Net cash used in investing activities (146,282) (10,618)
Net increase in cash and cash equivalents 8,473,070 5,212,541 Cash and cash equivalents at beginning of year 12,802,192 7,589,651 Cash and cash equivalents at end of year $ 21,275,262 $ 12,802,192
18 Prostate cancer foundation Report of Independent Auditors
Board of Directors Prostate Cancer Foundation
We have audited the statements of financial position of Prostate Cancer Foundation (the Foundation) as of December 31, 2007 and 2006, and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Foundation’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation at December 31, 2007 and 2006, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.
July 15, 2008
19 Progress Report
Board of Directors Stuart (Skip) Holden, M.D. Nelson Peltz Leadership Team Director, Louis Warschaw Chairman and Michael Milken Prostate Cancer Center Chief Executive Officer Jonathan W. Simons, M.D. Founder and Chairman Cedars Sinai Medical Center Triarc Companies, Inc. President and Prostate Cancer Foundation Chief Executive Officer Arthur Kern Lynda Resnick David H. Koch Chair Charles F. Baird, Jr. Investor Vice Chairman Managing Partner Roll International Ralph Finerman North Castle Partners David Hamilton Koch Chief Financial Officer, Executive Vice President Bert Roberts, Jr. Treasurer and Secretary James Blair Koch Industries Consultant General Partner Stuart Holden, M.D. Domain Associates The Honorable Earle Mack Richard Sandler Medical Director Senior Partner Vice President Steven A. Burd The Mack Company Maron & Sandler Howard R. Soule, Ph.D. Chairman, President and Executive Vice President Executive Vice President and Chief Executive Officer Jeffrey A. Marcus Milken Family Foundation Chief Science Officer Safeway, Inc. Managing Director Crestview Advisors J. Gary Shansby Helen Hsieh David Ederer Chairman Vice President Chairman Shmuel Meitar Partida Tequila, LLC Finance and Administration Ederer Investment Company Director Aurec Group Elaine Wynn Jan Haber David J. Epstein Director Vice President Founder Leslie D. Michelson Wynn Resorts Events and Donor Relations ACS Clearinghouse Chief Executive Officer National Chairman Private Health Management Communities-in-Schools Dave Perron R. Christian B. Evensen Vice President Partner Lori Milken Stanley Zax Baseball and Sports Enterprises Flintridge Capital Investments, Vice President President and Chairman LLC Prostate Cancer Foundation Zenith National Insurance Corp. Dan Zenka, APR Vice President Peter T. Grauer Jerry Monkarsh Communications Presidential Board Chairman Partner Bloomberg, LP EJM Development Jimmy Carter The Reverend Rosey Grier Henry Nordhoff George H.W. Bush The Milken Family Foundation Chairman, President and Chief Executive Officer Gen-Probe Incorporated Bill Clinton
20
Inspiring Hope
With her personal donation of twenty dollars, 12-year-old Olivia L. from Goleta, California became another important member of PCF’s Community of everyday heroes fighting to end suffering and death from prostate cancer. Donors from all walks of life, brilliant researchers, passionate supporters and dedicated staff are enabling the Prostate Cancer Foundation to leverage critical resources, accelerate scientific discovery and inspire hope for millions of prostate cancer patients and their families.
pcf.org & $!" ! $#! $ ! % !"#" #! " $!" !' % !! %%%" ! !# 1250 Fourth Street Santa Monica, CA 90401 Tel 800.757.CURE (2873) Fax 310.570.4701 ( !"# #%!" $